Author: limitlessbeliefsstaff

Nigeria needs sustainable clean water solutions which eliminate carbon-intensive supply chains and environmentally harmful plastic wastes. Data from development organisations have indicated the need for the country to improve the quality of drinking water for health reasons, among others. As such, a global leader in atmospheric drinking water generating devices, Watergen recently launched in Nigeria, … Read More “How atmospheric water generators will improve quality drinking water for all Nigerians.” »

In a significant development at the forefront of medical innovation, an innovative AI-generated drug is commencing human clinical trials in Hong Kong. This milestone represents a remarkable leap forward in utilizing artificial intelligence to accelerate drug discovery and revolutionize healthcare. CNBC, Hayden Field stated that Insilico Medicine, a Hong Kong-based biotech startup with $400 million … Read More “AI-Generated Drug Initiates Human Clinical Trials in Hong Kong” »

Kenyan e-health startup MyDawa has raised $20 million from private equity investor Alta Semper Capital to expand its regional reach and product offerings with the aim of becoming an all-in-one health platform for users. MyDawa, which launched in 2016, has diversified from an e-pharmacy to include online and in-person consultations, as well as laboratory services … Read More “Kenya’s MyDawa aims to be an all-in-one health platform backed by $20 million funding” »

The 14-sided polygon Tile(1,1), on the left, is known as a weakly chiral aperiodic monotile — in other words, if tilings that mix unreflected and reflected tiles are forbidden, then it tiles only aperiodically. However, by modifying its edges, as shown in the centre and right, strictly chiral aperiodic monotiles called “spectres” are created that … Read More “Researchers discover a single shape that tiles the plane aperiodically without reflection” »

A greater proportion of patients achieved 100 percent improvement in skin clearance at the highest dose level tested compared to placebo, at week 16 Phase 3 clinical development in moderate-to-severe plaque psoriasis is planned SPRING HOUSE, Pa., July 4, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced … Read More “Janssen Announces Positive Topline Results for JNJ-2113–a Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis” »